Basic Information
| LncRNA/CircRNA Name | FENDRR |
| Synonyms | FENDRR, FOXF1-AS1, TCONS_00024240, lincFOXF1, onco-lncRNA-21 |
| Region | GRCh38_16:86474529-86509099 |
| Ensemble | ENSG00000268388 |
| Refseq | NR_033925 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | neuroendocrine prostate cancer |
| ICD-0-3 | NA |
| Methods | RNA-seq, Microarray, qPCR etc. |
| Sample | neuroendocrine prostate cancer tissues |
| Expression Pattern | down-regulated |
| Function Description | Top candidate lncRNAs FENDRR, H19, LINC00514, LINC00617, and SSTR5-AS1 identified in this study are implicated in the development of NEPC. |
| Pubmed ID | 29757368 |
| Year | 2018 |
| Title | The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. |
External Links
| Links for FENDRR | GenBank HGNC NONCODE |
| Links for neuroendocrine prostate cancer | OMIM COSMIC |